Geron Rises as Imetelstat Helps Against Myelofibrosis
This article is for subscribers only.
Geron Corp. gained the most in more than a decade after the biotechnology company’s experimental drug for myelofibrosis, a bone marrow disorder, helped patients in a study.
Geron increased 45 percent to $5.21 at the close in New York, its biggest single-day advance since September 2003. The shares of the Menlo Park, California-based company have more than tripled this year.